Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevacizumab given before neoadjuvant doxorubicin/cyclophosphamide (AC) produced higher pathologic complete response (pCR) rates in triple- negative breast cancer (TNBC) compared with historical results achieved with standard anthracycline/taxane regimens. Patients and Methods: Eligible patients with operable TNBC ≥2 cm received four cycles of carboplatin (area under the curve 6, day 1) plus nab-paclitaxel (100 mg/m2, days 1, 8 and 15) every 28 days, followed by four 14-day cycles of AC neoadjuvantly, with bevacizumab 10 mg/kg every 14 days for the rst 6 cycles of neoadjuvant chemotherapy, resuming postoperatively to complete 1 year of antibody trea...
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with r...
BACKGROUND: CALGB (Alliance) 40603 measured the effects of adding carboplatin (Cb) and/or bevacizuma...
Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) r...
Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevaci...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...
Purpose: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete...
BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in tripl...
Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients ...
PURPOSE: Triple negative breast cancer (TNBC) patients frequently receive neoadjuvant chemotherapy (...
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxan...
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxan...
<div><p>Triple negative breast cancer (TNBC) is associated with high pathological complete remission...
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with r...
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with r...
BACKGROUND: CALGB (Alliance) 40603 measured the effects of adding carboplatin (Cb) and/or bevacizuma...
Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) r...
Purpose: This phase II neoadjuvant study investigated whether nab paclitaxel, carboplatin and bevaci...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...
One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response...
Purpose: One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete...
BACKGROUND: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in tripl...
Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients ...
PURPOSE: Triple negative breast cancer (TNBC) patients frequently receive neoadjuvant chemotherapy (...
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxan...
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxan...
<div><p>Triple negative breast cancer (TNBC) is associated with high pathological complete remission...
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with r...
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with r...
BACKGROUND: CALGB (Alliance) 40603 measured the effects of adding carboplatin (Cb) and/or bevacizuma...
Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) r...